Author

Anna J. Barget

University of Michigan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Organism:Drosophila· 1 Research Focus:drug response / drug discovery· 1 Assay:electronic health records· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Henry Lauris PaulsoniD· 2 shared Maria do Carmo CostaiD· 2 shared Anjesh GhimireiD· 1 shared Bedri RanxhiiD· 1 shared Brendon O. WatsoniD· 1 shared Emily D. Shaw· 1 shared Joanna R. SuttoniD· 1 shared Kozeta Libohova· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Henry Lauris PaulsonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Sleep alterations in a mouse model of Spinocerebellar ataxia type 3

Maria-Efstratia Tsimpanouli, Anjesh Ghimire, Anna J. Barget, Ridge Weston, Henry Lauris Paulson, Maria do Carmo Costa, Brendon O. Watson

This study quantifies sleep EEG changes in a SCA3 mouse model, finding increased REM duration, beta power, and spectral alterations in homozygous mice compared to wild-type.

Cells · Oct 5, 2022Peer-reviewedNeuroscience

Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia Type 3 disease protein

Naila S. Ashraf, Joanna R. Sutton, Yemen Yang, Bedri Ranxhi, Kozeta Libohova, Emily D. Shaw, Anna J. Barget, Sokol V. Todi, Henry Lauris Paulson, Maria do Carmo Costa

The paper identifies 15 druggable genes that modulate ATXN3 levels and toxicity in SCA3, with FBXL3/SCF pathway showing potential as a therapeutic target.

Neurobiology of Disease · Nov 26, 2019Peer-reviewedNeuroscience